Systematic review and meta-analysis: Do clinical trials testing antimuscarinic agents for overactive bladder adequately measure central nervous system adverse events?

Journal of the American Geriatrics Society

Volumn 59, Issue 7, 2011, Pages 1332-1339

  Paquette, Amélie ^a   Gou, Pauline ^a   Tannenbaum, Cara ^a  

^a CENTRE DE RECHERCHE   (Canada)

Author keywords

antimuscarinic agents; central nervous system safety; reporting bias; systematic review

Indexed keywords

DARIFENACIN; FESOTERODINE; MUSCARINIC RECEPTOR BLOCKING AGENT; OXYBUTYNIN; PROPIVERINE; SOLIFENACIN; TOLTERODINE; TROSPIUM CHLORIDE;

ARTICLE; CLINICAL TRIAL (TOPIC); CONFUSION; DIZZINESS; DRUG EFFECT; DRUG FORMULATION; EMBASE; HUMAN; INSOMNIA; MEDLINE; MINI MENTAL STATE EXAMINATION; OVERACTIVE BLADDER; SOMNOLENCE; SYSTEMATIC ERROR;

AGED; BRAIN; CLINICAL TRIALS AS TOPIC; HUMANS; MUSCARINIC ANTAGONISTS; RESEARCH DESIGN; URINARY BLADDER, OVERACTIVE;

EID: 79960422777     PISSN: 00028614     EISSN: 15325415     Source Type: Journal    
DOI: 10.1111/j.1532-5415.2011.03473.x     Document Type: Article

References (30)

1. Irwin DE, Milsom I, Hunskaar S, et al,. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: Results of the EPIC study. Eur Urol 2006; 50: 1306-1314; discussion 1314-1305.
2. Abrams P, Cardozo L, Fall M, et al,. The standardisation of terminology in lower urinary tract function: Report from the Standardisation Sub-committee of the International Continence Society. Urology 2003; 61: 37-49. (Pubitemid 36151708)
3. Stewart WF, Van Rooyen JB, Cundiff GW, et al,. Prevalence and burden of overactive bladder in the United States. World J Urol 2003; 20: 327-336. (Pubitemid 44175300)
4. Brown JS, Vittinghoff E, Wyman JF, et al,. Urinary incontinence: Does it increase risk for falls and fractures? Study of Osteoporotic Fractures Research Group. J Am Geriatr Soc 2000; 48: 721-725. (Pubitemid 30457407)
5. Morris V, Wagg A., Lower urinary tract symptoms, incontinence and falls in elderly people: Time for an intervention study. Int J Clin Pract 2007; 61: 320-323.
6. Chapple CR, Khullar V, Gabriel Z, et al,. The effects of antimuscarinic treatments in overactive bladder: An update of a systematic review and meta-analysis. Eur Urol 2008; 54: 543-562.
7. Kay GG, Abou-Donia MB, Messer WS Jr., et al,. Antimuscarinic drugs for overactive bladder and their potential effects on cognitive function in older patients. J Am Geriatr Soc 2005; 53: 2195-2201. (Pubitemid 43001205)
8. Klausner AP, Steers WD., Antimuscarinics for the treatment of overactive bladder: A review of central nervous system effects. Curr Urol Rep Nov 2007; 8: 441-447. (Pubitemid 350144521)
9. Abrams P, Andersson KE, Buccafusco JJ, et al,. Muscarinic receptors: Their distribution and function in body systems, and the implications for treating overactive bladder. Br J Pharmacol 2006; 148: 565-578. (Pubitemid 43993048)
10. Bymaster FP, McKinzie DL, Felder CC, et al,. Use of M1-M5 muscarinic receptor knockout mice as novel tools to delineate the physiological roles of the muscarinic cholinergic system. Neurochem Res 2003; 28: 437-442. (Pubitemid 36314830)
11. Kay G, Crook T, Rekeda L, et al,. Differential effects of the antimuscarinic agents darifenacin and oxybutynin ER on memory in older subjects. Eur Urol 2006; 50: 317-326. (Pubitemid 44038078)
12. Wesnes KA, Edgar C, Tretter RN, et al,. Exploratory pilot study assessing the risk of cognitive impairment or sedation in the elderly following single doses of solifenacin 10 mg. Expert Opin Drug Saf 2009; 8: 615-626.
13. Staskin D, Kay G, Tannenbaum C, et al,. Trospium chloride has no effect on memory testing and is assay undetectable in the central nervous system of older patients with overactive bladder. Int J Clin Pract 2010; 64: 1294-1300.
14. Katz IR, Sands LP, Bilker W, et al,. Identification of medications that cause cognitive impairment in older people: The case of oxybutynin chloride. J Am Geriatr Soc 1998; 46: 8-13. (Pubitemid 28037667)
15. Liberati A, Altman DG, Tetzlaff J, et al,. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: Explanation and elaboration. PLoS Med 2009; 6: e1000100.
16. Higgins JP, Thompson SG, Deeks JJ, et al,. Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557-560. (Pubitemid 37088507)
17. Minassian VA, Ross S, Sumabat O, et al,. Randomized trial of oxybutynin extended versus immediate release for women aged 65 and older with overactive bladder: Lessons learned from conducting a trial. J Obstet Gynaecol Can 2007; 29: 726-732.
18. Wagg A, Wyndaele JJ, Sieber P., Efficacy and tolerability of solifenacin in elderly subjects with overactive bladder syndrome: A pooled analysis. Am J Geriatr Pharmacother 2006; 4: 14-24.
19. Chapple C, DuBeau C, Ebinger U, et al,. Darifenacin treatment of patients >or=65 years with overactive bladder: Results of a randomized, controlled, 12-week trial. Curr Med Res Opin 2007; 23: 2347-2358. (Pubitemid 350033436)
20. Malone-Lee JG, Walsh JB, Maugourd MF., Tolterodine: A safe and effective treatment for older patients with overactive bladder. J Am Geriatr Soc 2001; 49: 700-705. (Pubitemid 32652460)
21. Zinner NR, Mattiasson A, Stanton SL., Efficacy, safety, and tolerability of extended-release once-daily tolterodine treatment for overactive bladder in older versus younger patients. J Am Geriatr Soc 2002; 50: 799-807. (Pubitemid 34496674)
22. Sand PK, Johnson Ii TM, Rovner ES, et al,. Trospium chloride once-daily extended release is efficacious and tolerated in elderly subjects (aged >/=75 years) with overactive bladder syndrome. BJU Int 2011; 107: 612-620.
23. Newman DK., The MATRIX study: Evaluating the data in older adults. Director 2008; 16: 15-19.
24. Staskin DR, Harnett MD., Effect of trospium chloride on somnolence and sleepiness in patients with overactive bladder. Curr Urol Rep 2004; 5: 423-426.
25. Kay GG, Wesnes KA., Pharmacodynamic effects of darifenacin, a muscarinic M selective receptor antagonist for the treatment of overactive bladder, in healthy volunteers. BJU Int 2005; 96: 1055-1062. (Pubitemid 41531414)
26. Lipton RB, Kolodner K, Wesnes K., Assessment of cognitive function of the elderly population: Effects of darifenacin. J Urol 2005; 173: 493-498.
27. Todorova A, Vonderheid-Guth B, Dimpfel W., Effects of tolterodine, trospium chloride, and oxybutynin on the central nervous system. J Clin Pharmacol 2001; 41: 636-644. (Pubitemid 32493358)
28. Diefenbach K, Donath F, Maurer A, et al,. Randomised, double-blind study of the effects of oxybutynin, tolterodine, trospium chloride and placebo on sleep in healthy young volunteers. Clin Drug Investig 2003; 23: 395-404. (Pubitemid 36724158)
29. Diefenbach K, Arold G, Wollny A, et al,. Effects on sleep of anticholinergics used for overactive bladder treatment in healthy volunteers aged >or=50 years. BJU Int 2005; 95: 346-349. (Pubitemid 40283121)
30. Tannenbaum C, Mayo N, Ducharme F., Older women's health priorities and perceptions of care delivery: Results of the WOW health survey. Can Med Assoc J 2005; 173: 153-159. (Pubitemid 41032510)